Skip to content
Finance Investment, Oil Mining Resources

Galan Lithium (ASX:GLN) – Maiden Filling of Pond 1 Commences at Hombre Muerto West

Galan Lithium Limited (ASX:GLN) 2 mins read

Galan Lithium Limited (ASX:GLN) ("Galan" or the "Company"), an ASX-listed lithium exploration and development business, is pleased to provide an update on the significant progress of its Hombre Muerto West (HMW) Phase 1 lithium brine project. The Company is on track to commence lithium chloride production in the first half of 2025.

 

Key Project Highlights:

  • Commencement of Pond 1 Filling: The initial filling of Pond 1 at the HMW Project marks a significant milestone in the project's development.
  • Evaporation Process Initiation: The evaporation process, a critical component of lithium production, is set to begin within two weeks following the completion of quality testing.
  • Rapid Progress in Construction: The liner installation in Pond 1 has achieved 40% completion, while Pond 2's earthworks construction is 20% complete.
  • Premium Grade Lithium Chloride Production: The HMW Project is poised to produce a high-grade lithium chloride concentrate of 6% Li, equivalent to 13% Li2O or 32% Lithium Carbonate Equivalent (LCE), positioning it as a tier-one project in the industry.
  • Competitive Cost Structure: With an operating cost of $US3,510/t LCE, translating to a low Li2O equivalent operating cost of SC6 $US310/t-$US350/t, HMW is positioned in the 1st quartile of the lithium industry’s cost curve.
  • Resource Estimate Update: An updated resource estimate for the HMW Project is scheduled for release in Q1 2024.

Phased Production Strategy:

The HMW project is structured into four production phases. The initial Phase 1 Definitive Feasibility Study (DFS) is focused on producing 5.4ktpa LCE of lithium chloride concentrate by H1 2025. Subsequent phases include:

  • Phase 2: Targeting 21ktpa LCE in 2026.
  • Phase 3: Aiming for 40ktpa LCE by 2028.
  • Phase 4: Projected to reach 60ktpa LCE by 2030, incorporating lithium brine from both HMW and Galan’s Candelas project.

The promising results of the Phase 2 DFS, announced on 3 October 2023, underscore the project's potential and scalability.

 

Galan’s Managing Director, Juan Pablo (JP) Vargas de la Vega, commented:

 

“Our experienced project team have been implementing a quicker route to start evaporation while construction continues for HMW Phase 1. We are taking advantage of the summer season whereby a buffer wall has been installed at the one third mark of Pond 1. The commencement of the filling of Pond 1 is another significant major milestone for the HMW project and I congratulate the entire Galan team. The initial partial evaporation process will commence in approximately 14 days with the full fill of Pond 1 remaining on track for Q1 2024.” 


About us:

Galan Lithium Limited (ASX:GLN) is an ASX-listed lithium exploration and development business. Galan’s flagship assets comprise two world-class lithium brine projects, HMW and Candelas, located on the Hombre Muerto Salar in Argentina, within South America’s ‘lithium triangle’. Hombre Muerto is proven to host lithium brine deposition of the highest grade and lowest impurity levels within Argentina. It is home to the established El Fenix lithium operation (Livent Corporation) and the Sal de Vida (Allkem) and Sal de Oro (POSCO) lithium projects. Galan is also exploring at Greenbushes South in Western Australia, approximately 3 km south of the Tier 1 Greenbushes Lithium Mine.


Contact details:

Jane Morgan

[email protected]

Media

More from this category

  • Finance Investment, Medical Health Aged Care
  • 17/03/2026
  • 10:25
Jane Morgan Management

NeuroScientific Biopharmaceuticals (ASX:NSB) Advances StemSmart(TM) Manufacturing Scale-Up as Phase 2 Crohn’s Disease Trial Preparations Progress

Perth, Australia – 17 March 2026 | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has reached an important development milestone with the commencement of the first technology transfer manufacturing run of its patented StemSmart™ mesenchymal stem cell (MSC) process at leading Australian cell therapy manufacturer Q-Gen Cell Therapeutics. The initiation of the manufacturing run represents a key step in the transfer of the StemSmart™ manufacturing process to a large-scale clinical contract manufacturer that is then capable of providing adequate supply for Phase 2 clinical trials and future commercialisation. Q-Gen Cell Therapeutics, located within the QIMR Berghofer Medical Research Institute in Brisbane, is one…

  • Contains:
  • Environment, Finance Investment
  • 17/03/2026
  • 10:21
HESTA

HESTA launches search for Australia’s early childhood education champions

17 March 2026 The search for Australia’s most outstanding early childhood educators is underway with nominations opening today for the 2026 HESTA Early Childhood…

  • Contains:
  • Finance Investment, Oil Mining Resources
  • 17/03/2026
  • 09:57
Jane Morgan Management

Moab to acquire additional uranium tenements at Manyoni Project in Tanzania

Perth, Australia – 17 March 2026 Moab Minerals Limited (ASX: MOM) has strengthened its position at the Manyoni Uranium Project in Tanzania after securing the transfer of four uranium tenements adjacent to the project area from AuKing Limited (ASX: AKN). The tenements have been transferred to Moab’s Tanzanian subsidiary, Katika Resources Limited, and expand the Company’s exploration footprint across a prospective palaeochannel uranium system already mineralised at Manyoni. The acquisition forms part of Moab’s strategy to consolidate a strategic uranium landholding in central Tanzania and advance exploration across multiple targets associated with the broader palaeo-drainage system. Historical drilling across the…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.